Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.45 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405381 | 1.00 | HTR2C (0.60) | HTR2CHRH3SMYD2CES2L3MBTL3 | |
| SCHEMBL13071662 | 0.92 | HTR2C (0.62) | HTR2CHRH3SMYD2CES2L3MBTL3 | |
| SCHEMBL3399560 | 0.92 | HTR2C (0.62) | HTR2CHRH3SMYD2CES2L3MBTL3 | |
| SCHEMBL3400254 | 0.91 | HTR2C (0.55) | HTR2CCES2L3MBTL1LMNA | |
| SCHEMBL3402125 | 0.89 | HTR2C (0.54) | HTR2CHRH3L3MBTL3L3MBTL1LMNA | |
| SCHEMBL3403891 | 0.89 | HTR2C (0.54) | HTR2CHRH3L3MBTL3L3MBTL1LMNA | |
| SCHEMBL3403900 | 0.87 | HTR2C (0.80) | HTR2CHRH3SMYD2CES2L3MBTL3 | |
| SCHEMBL13071647 | 0.87 | HTR2C (0.80) | HTR2CHRH3SMYD2CES2L3MBTL3 | |
| SCHEMBL3404356 | 0.87 | HTR2C (0.61) | HTR2CHRH3CES2L3MBTL3L3MBTL1 | |
| SCHEMBL13071740 | 0.87 | HTR2C (0.61) | HTR2CHRH3CES2L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006089076-A9 | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | HTR2C 416/4885HRH3 1/4885SMYD2 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.